HOME >> MEDICINE >> NEWS
UCLA studies experimental cancer drug

Men with high-risk prostate cancer who are candidates for surgery are being sought to test a molecularly targeted experimental drug that may interrupt the signal that is driving their cancer and keep the disease from recurring.

The early-phase clinical trial is based on basic research discoveries made in Jonsson Cancer Center laboratories. UCLA researchers have successfully tested the drug in laboratory and animal models. They hope to translate that benefit into patients in the clinic, said Dr. Charles Sawyers, co-principal investigator for the study and the Jonsson Cancer Center scientist whose basic research resulted in the clinical trial.

UCLA laboratory studies have shown that some patients with prostate cancer have lost PTEN, a tumor-suppressor gene. In some patients who have lost PTEN, a gene called mTOR located downstream in the cell-signaling pathway gets turned on and may be driving the cancer. Sawyers, along with co-principal investigator Dr. Robert Reiter, will test a drug called CCI779, which they believe targets mTOR.

"We discovered that tumors missing PTEN seem to be very responsive to CCI779, and it's very clear at a molecular biology level why," Sawyers said. "When you've lost PTEN, mTOR activity gets turned up and tumors become dependent on it for their growth. So a drug that inhibits mTOR should impact the tumor cells but have no effect on the normal cells."

Armed with his laboratory discoveries, Sawyers proposed the prostate cancer study to Wyeth Pharmaceuticals, and the clinical trial was designed. UCLA's Jonsson Cancer Center is the only West Coast site offering this study. Other sites participating include MD Anderson Cancer Center in Texas and Fox Chase Cancer Center in Philadelphia, Sawyers said.

Because CCI779 targets only what is broken in the cancer cell, it is expected to cause very few side effects, Sawyers said.

UCLA researchers are seeking study volunteers with newly diagnosed prostate ca
'"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
4-Dec-2003


Page: 1 2

Related medicine news :

1. New studies suggest airborne SARS transmission is possible
2. New studies show mixed results on epilepsy drugs and birth defects
3. Brain imaging studies investigate pain reduction by hypnosis
4. Impact of scientific advances on drug studies and membrane research to be explored
5. Two studies find evidence that sunlight may have beneficial influence on cancer
6. More studies on risks and benefits of COX-2 inhibitors published in Archives of Internal Medicine
7. Animal studies show stem cells might make biological pacemaker
8. Infants, children prefer sounds over pictures and only slowly become visually oriented, studies find
9. New studies on Ritalin and Alzheimers Disease highlight ACNP Annual Meeting
10. Gender and sex hormones affect the brains pain response and more, according to new studies
11. Analysis of tamoxifen studies reveals slight increase of stroke risk

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: UCLA studies experimental cancer drug

(Date:9/3/2015)... IN (PRWEB) , ... September 03, 2015 , ... ... Rochester, MN, and Indiana University, Indianapolis, have chosen Center for Hospice Care ... from these institutions will train at CHC as part of fulfilling their requirements ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... in Haiti, has partnered with Slingshot® Product Development Group to manufacture a long-lasting ... water. Michael Wahl with DriButts plans to bring 600 DriButts Diapers to rural ...
(Date:9/3/2015)... ... September 03, 2015 , ... Results of a comprehensive survey ... and Policy Analysis has found physician leadership development training programs to be growing ... respondents said their organizations conduct some kind of physician leadership development program, another ...
(Date:9/3/2015)... , ... September 03, 2015 , ... ... community to be situated at 4400 Columbine Drive in Bellingham, Washington. Silverado Bellingham, ... and has been carefully designed to serve up to 80 people living with ...
(Date:9/3/2015)... ... September 03, 2015 , ... IQ Formulations today ... by economic development group GrowFL and the Edward Lowe Foundation. The leading health ... this prestigious award, which recognizes growing second-stage companies “that demonstrate high performance in ...
Breaking Medicine News(10 mins):Health News:Physicians from Mayo Clinic and Indiana University to Complete Hospice & Palliative Medicine Training at Center for Hospice Care 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 3Health News:Survey finds growing movement for physician leadership training 2Health News:Survey finds growing movement for physician leadership training 3Health News:Site Dedication Ceremony to Celebrate New Silverado Memory Care Community 2Health News:IQ Formulations Hailed Among Florida Companies to Watch for 2015 2Health News:IQ Formulations Hailed Among Florida Companies to Watch for 2015 3
(Date:9/3/2015)... About dry eye syndrome Dry eye ... deficient tear production or quick tear evaporation or deviation ... aqueous tear deficient dry eye and evaporative dry eye. ... not produce enough tears, whereas meibomian gland dysfunction results ... slow tear evaporation and maintain tear stability. The symptoms ...
(Date:9/3/2015)... , Sept. 3, 2015  WellCare Health Plans, Inc. ... Asher , senior vice president and chief financial officer, ... 2015 Healthcare Conference on Wednesday, September 9, 2015, at ... be webcast live. In addition, a replay of the ... live broadcast. Both the live broadcast and the replay ...
(Date:9/3/2015)... ALISO VIEJO, Calif. , Sept. 3, ... a leading global pharmaceutical company, and AqueSys, Inc. ... on developing ocular implants that reduce intraocular pressure ... have entered into an agreement under which Allergan ... the terms of the agreement, Allergan will acquire ...
Breaking Medicine Technology:Global Dry Eye Syndrome Market 2015-2019 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 3Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 4Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 5Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 6
Cached News: